ROSETTA INPHARMATICS, INC.
Previous company name
Name change date
Rosetta Inpharmatics, LLC is a privately held company engaged in commercial physical and biological research. The company was founded in 1996 to design and implement DNA microarray gene expression technologies. It has its registered head office located in Seattle, Washington.
Rosetta Inpharmatics develops and implements technologies that will improve drug discovery. The company’s leading-edge genomic research and data analysis efforts focus on how medical compounds affect biology, enabling more accurate selection of drug targets and more efficient drug development. Rosetta’s Biosoftware unit develops sophisticated gene and protein expression analysis software – sold as Rosetta Resolver (gene expression) and Rosetta Elucidator (protein expression) that manages the large amount of physical data generated by biotech research scientists. The company was established with the goal to overcome the problems limiting the discovery and effective development of pharmaceutical and agricultural products.
Rosetta Inpharmatics is a wholly owned subsidiary of Merck & Co Inc, a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of products to improve human and animal health.
Rosetta Inpharmatics, Inc. is engaged in the emerging field of informational genomics. Informational genomics involves acquiring, storing, and analyzing gene expression information gathered from throughout a cell to identify a majority of the medically important drug targets and gene functions. The Company’s technology platform consists of the Rosetta Resolver Expression Data Analysis System, high-throughput gene expression profiling utilizing its FlexJet DNA microarray technology and coherent data sets of information generated from microarrays. The Company generates revenue by providing its technologies as separate components sold as products either by itself or its partners or as an integrated platform as a part of research collaborations with pharmaceutical, biotechnology and agricultural customers.
Description and history
Rosetta Inpharmatics, Inc., incorporated in December 1996 as Rosetta Biosystems Inc., is engaged in the field of informational genomics. Informational genomics involves acquiring, storing, and analyzing gene expression information gathered from throughout a cell to identify a majority of the medically important drug targets and gene functions. The Company’s technology platform consists of the Rosetta Resolver Expression Data Analysis System, high-throughput gene expression profiling utilizing its FlexJet DNA microarray technology and coherent data sets of information generated from microarrays. The Company generates revenue by providing its technologies as separate components sold as products either by itself or its partners or as an integrated platform as a part of research collaborations with pharmaceutical, biotechnology and agricultural customers.
Rosetta Resolver Expression Data Analysis System
The Rosetta Resolver System is an integrated, enterprise-wide solution for storing, retrieving and analyzing large quantities of gene expression data generated using cDNA microarrays, oligonucleotide microarrays and other technologies. Its architecture supports the concurrent analysis and comparison of tens of thousands of expression profiling experiments and is designed to accommodate the increasing diversity of data types and analysis algorithms.
The Rosetta Resolver System enables users to securely assemble, store in a single database and analyze gene expression data from multiple expression technology platforms. The product’s flexible interfaces allow users to add, edit and maintain cell type, RNA and experiment annotations, and to collaborate and share information with other users. The Rosetta Resolver System provides tools to find and analyze expression profiling information quickly and efficiently through custom database queries. Users of the Rosetta Resolver System can instantly link to expression profile databases and other databases on corporate Intranets or the Internet.
The Company offers professional bioinformatics services to integrate the Rosetta Resolver System with its customers’ unique enterprise resources, to produce state-of-art expression profile data, and to develop special analysis software for their research needs. The Rosetta Resolver System is jointly marketed by Agilent and the Company and is being sold by Agilent pursuant to its collaboration agreement.
High-Throughput Gene Expression Profiling
In 2000, the Company opened a 14,000 square foot, high-throughput production facility that has been designed to perform up to 100,000 microarray experiments annually. This facility leverages the Company’s biological expertise, including experimental design, informatics expertise in data mining, and proprietary coherent data sets, by industrializing gene expression profiling. Gene expression profiling is a key component of the Company’s performance obligations under its collaboration agreements. A significant element of the Company’s gene expression profiling capability is its proprietary Flexjet DNA microarray technology.
FlexJet DNA microarrays consist of different DNA sequences built up at tens of thousands of different positions on glass slides using a modified inkjet printer head to deliver the individual DNA building blocks G, C, A or T to the appropriate locations. This inkjet technology is fast, flexible, reproducible and economical and it can produce new array designs in a matter of hours, which is significantly faster than mask-based or spotter-based array technologies. Flexjet DNA microarrays use oligonucleotides synthesized directly on glass slides.
Prior to synthesizing its FlexJet DNA microarrays, the Company performs extensive calculations to determine the possible interactions between DNA sequences in the genome to choose the oligonucleotide probes that will report the desired genes and no others. This process, coupled with the high accuracy with which the oligonucleotide sequences are synthesized, allows sensitive and specific gene expression reporting using only a single reporter feature per gene. This, in turn, allows more than 25,000 genes to be monitored using a single microscope slide.
Coherent Data Sets and Reference Libraries
The Company builds coherent sets of data generated from DNA microarrays that represent the responses of cells to different genetic and disease states and to drug treatments. These data sets provide detailed references against which other expression measurements, either generated by the Company or by its collaborators or customers, can be compared. Using its extensive experience, the Company has developed experiment protocols, process controls and analysis techniques that allow the sharing of data between experiments. This coherence requirement is a key aspect of the Company’s reference library approach. Data that have not been derived using this rigorous approach are much less valuable.
Integrated Professional Services
The Company combines its informational genomics tools together with its consulting services to provide enhanced value to selected customers. These services include customization of the Rosetta Resolver System, customized FlexJet DNA microarrays and creation of highly accurate and coherent data sets. The integration of the Company’s unique tools and expertise presents significant capabilities to customers desiring the power of informational genomics technologies.
Founded to design and implement DNA microarray gene expression technologies
Develops and implements technologies that will improve drug discovery
US SIC Code
12040, 115th Avenue N.E.
City province or state postal code
98034, KIRKLAND, WA
Phone: +1 425 820 8900
Fax: +1 425 821 5354
Country address: UNITED STATES OF AMERICA
Website url: www.rii.com